NCPE Ireland HTA for Opdualag (nivolumab+relatlimab) for advanced melanoma: status update (ncpe.ie)

• HTA status: Awaiting response from applicant.
• Indication: First-line advanced melanoma with PD-L1 <1%.
• Timeline: Rapid review April 2024, full submission December 2025, preliminary review April 2026.

"The National Centre for Pharmacoeconomics (NCPE) in Ireland has published an update on its health technology assessment of nivolumab+relatlimab (Opdualag) for first-line treatment of advanced melanoma in patients with PD-L1 expression less than 1%. The assessment is currently awaiting a response from the applicant. A rapid review completed in April 2024 recommended a full HTA, which was commissioned in May 2024. The full submission was received in December 2025, and a preliminary review was sent in April 2026. The assessment re-commenced in May 2026, with a follow-up sent on 22 May 2026. The HTA ID is 24009."